Chemed Corp. (NYSE:CHE)‘s stock had its “outperform” rating reaffirmed by stock analysts at Oppenheimer Holdings Inc. in a research report issued on Tuesday. They currently have a $155.00 price target on the stock. Oppenheimer Holdings Inc.’s target price would indicate a potential upside of 9.15% from the company’s current price.
Other equities analysts also recently issued research reports about the stock. JMP Securities reaffirmed a “hold” rating on shares of Chemed Corp. in a research note on Sunday, September 4th. RBC Capital Markets reissued a “sector perform” rating and set a $162.00 target price (up previously from $136.00) on shares of Chemed Corp. in a research note on Wednesday, July 27th. Zacks Investment Research raised shares of Chemed Corp. from a “hold” rating to a “buy” rating and set a $167.00 target price for the company in a research note on Thursday, July 28th. Finally, Royal Bank Of Canada lifted their target price on shares of Chemed Corp. from $136.00 to $162.00 and gave the stock a “sector perform” rating in a research note on Wednesday, July 27th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Chemed Corp. presently has a consensus rating of “Hold” and an average target price of $161.50.
Shares of Chemed Corp. (NYSE:CHE) traded down 0.80% during midday trading on Tuesday, reaching $140.88. 38,434 shares of the company’s stock traded hands. The stock has a market cap of $2.28 billion, a P/E ratio of 22.34 and a beta of 1.14. The stock has a 50 day moving average of $137.05 and a 200-day moving average of $135.62. Chemed Corp. has a 12 month low of $124.77 and a 12 month high of $160.12.
Chemed Corp. (NYSE:CHE) last released its quarterly earnings results on Monday, July 25th. The company reported $1.80 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.72 by $0.08. The firm earned $290 million during the quarter, compared to the consensus estimate of $393.50 million. Chemed Corp. had a net margin of 6.93% and a return on equity of 24.12%. The company’s revenue for the quarter was up 2.2% on a year-over-year basis. During the same quarter last year, the firm earned $1.71 earnings per share. On average, equities research analysts forecast that Chemed Corp. will post $7.25 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Friday, September 2nd. Shareholders of record on Monday, August 15th were issued a $0.26 dividend. This represents a $1.04 dividend on an annualized basis and a yield of 0.73%. This is a boost from Chemed Corp.’s previous quarterly dividend of $0.24. The ex-dividend date was Thursday, August 11th. Chemed Corp.’s dividend payout ratio (DPR) is presently 16.51%.
In other Chemed Corp. news, insider Spencer S. Lee sold 2,000 shares of the firm’s stock in a transaction on Thursday, September 22nd. The shares were sold at an average price of $141.67, for a total value of $283,340.00. Following the completion of the sale, the insider now directly owns 39,867 shares in the company, valued at $5,647,957.89. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Kevin J. Mcnamara sold 18,000 shares of the firm’s stock in a transaction on Wednesday, August 3rd. The stock was sold at an average price of $144.87, for a total transaction of $2,607,660.00. Following the completion of the sale, the insider now owns 163,266 shares of the company’s stock, valued at $23,652,345.42. The disclosure for this sale can be found here. 5.32% of the stock is currently owned by company insiders.
A number of large investors have recently bought and sold shares of CHE. Vanguard Group Inc. boosted its stake in Chemed Corp. by 3.1% in the second quarter. Vanguard Group Inc. now owns 1,576,155 shares of the company’s stock worth $214,846,000 after buying an additional 46,726 shares during the last quarter. FMR LLC boosted its stake in Chemed Corp. by 1.0% in the second quarter. FMR LLC now owns 828,351 shares of the company’s stock worth $112,913,000 after buying an additional 8,351 shares during the last quarter. Gamco Investors INC. ET AL boosted its stake in Chemed Corp. by 0.5% in the second quarter. Gamco Investors INC. ET AL now owns 644,007 shares of the company’s stock worth $87,785,000 after buying an additional 2,940 shares during the last quarter. Acadian Asset Management LLC boosted its stake in Chemed Corp. by 1.7% in the second quarter. Acadian Asset Management LLC now owns 594,357 shares of the company’s stock worth $81,018,000 after buying an additional 10,057 shares during the last quarter. Finally, Investec Asset Management LTD boosted its stake in Chemed Corp. by 3.0% in the first quarter. Investec Asset Management LTD now owns 559,973 shares of the company’s stock worth $75,848,000 after buying an additional 16,304 shares during the last quarter. Institutional investors and hedge funds own 98.62% of the company’s stock.
About Chemed Corp.
Chemed Corporation operates and divests subsidiaries engaged in diverse business activities. The Company operates its business in two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS segment provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with MarketBeat.com's FREE daily email newsletter.